Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us ![]()
About
Not Confirmed
Not Confirmed
24-26 February, 2026
BIO Partnering at JPMBIO Partnering at JPM
Not Confirmed
Not Confirmed
12-15 January, 2026
Biotech ShowcaseBiotech Showcase
Not Confirmed
Not Confirmed
12-14 January, 2026
List your booth number for exhibitions, ask us
CONTACT DETAILS





Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Industry Trade Show
Not Confirmed
24-26 February, 2026
BIO Partnering at JPMBIO Partnering at JPM
Industry Trade Show
Not Confirmed
12-15 January, 2026
Biotech ShowcaseBiotech Showcase
Industry Trade Show
Not Confirmed
12-14 January, 2026
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Derived from Mesenchymal stem cells obtained from donated umbilical cord tissue, Mesocel is set to treat patients suffering from life-threatening Covid-19 pneumonia and acute respiratory distress.
Lead Product(s): Human Umbilical Cord Derived Mesenchymal Stem Cell
Therapeutic Area: Infections and Infectious Diseases Brand Name: Mesocel
Study Phase: Phase I/ Phase IIProduct Type: Cell & Gene Therapy
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 15, 2021

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Human Umbilical Cord Derived Mesenchymal Stem Cell
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
LifeCell’s Mesocel Gets Nod for Clinical Trial from DCGI; Therapy to Treat Patients with Moderat...
Details : Derived from Mesenchymal stem cells obtained from donated umbilical cord tissue, Mesocel is set to treat patients suffering from life-threatening Covid-19 pneumonia and acute respiratory distress.
Product Name : Mesocel
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
September 15, 2021

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Indocyanine Green is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Carcinoma, Intraductal, Noninfiltrating.
Lead Product(s): Indocyanine Green
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: UndisclosedProduct Type: Miscellaneous
Recipient: Washington University School of Medicine
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 25, 2013

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Indocyanine Green
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Recipient : Washington University School of Medicine
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Indocyanine Green is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Carcinoma, Intraductal, Noninfiltrating.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 25, 2013

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Excipients
ABOUT THIS PAGE